Compare Medtronic PLC (MDT) vs MPLX LP (MPLX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Medtronic PLC vs MPLX LP — how do they compare? Medtronic PLC trades at $88.48 (market cap $112.24B), while MPLX LP trades at $56.3 (market cap $58.11B). The key difference: Medtronic PLC is the larger of the two by market cap, and MPLX LP pays the higher dividend (7.51%). Which is the better fit depends on your goals.
| MDT | MPLX | |
|---|---|---|
Market Cap | $112.24B | $58.11B |
Volume | 105,663,236 | 687,483 |
Sector | Health | Energy |
52-Week High | $105.35 | $60.51 |
52-Week Low | $73.75 | $47.80 |
Typical Hold Time | 63 Days | — |
Enterprise Value | $131.58B | $83.22B |
Dividend Yield | 3.28% | 7.51% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Medtronic (MDT) trades at $87.75, up 2.62% today, with strong fundamental performance including three consecutive quarterly earnings beats and a 49-year dividend growth streak. The stock shows bearish technical signals but maintains solid profitability with 13.93% net margins and positive cash flow trends. Recent regulatory approvals for medical devices and raised guidance signal operational momentum despite mixed technical indicators.
Outlook remains positive with analyst consensus at $97.80 (11% upside) and no sell ratings, though technical weakness and increasing debt-to-asset ratios pose near-term risks. The 3.2% dividend yield provides income support while revenue growth acceleration to $37.5B projected for 2026 offers growth potential.
MPLX trades at $57.32, up 0.47% with a bearish technical signal despite strong fundamentals. The company maintains robust profitability with 40.45% net income margin and 33.95% ROE, supported by $4.91B net income in 2025. Recent earnings show mixed results with a Q4 2025 beat but Q1 and Q2 2026 misses. Analyst consensus remains strongly bullish with 19 buy ratings and a $63.80 price target, representing 11.3% upside potential.
The investment case balances strong cash flow generation and dividend stability against energy market volatility risks. MPLX's fee-based midstream model provides revenue resilience, though technical indicators suggest near-term pressure. The 67.86% buy rating consensus indicates Wall Street confidence in the company's ability to maintain distribution growth despite recent earnings volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Medtronic PLC
One of the largest medical device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, heart valves, stents, insulin pumps, spinal fixation devices, neurovascular products, advanced energy, and surgical tools. The company markets its products to healthcare institutions and physicians in the United States and overseas. Foreign sales account for almost 50% of the company's total sales.
Read more on MDT →About MPLX LP
MPLX LP is a Master Limited Partnership (MLP) formed by Marathon Petroleum Corporation (MPC). It is a diversified, growth-oriented company primarily engaged in the gathering, processing, and transportation of natural gas and natural gas liquids (NGLs), as well as the transportation, storage, and distribution of crude oil and refined petroleum products. MPLX owns and operates a network of midstream energy infrastructure assets, providing essential services to the energy industry across the United States.
Read more on MPLX →
